As Part of the Evolving CiPA Paradigm, the FDA Publishes Results...

Working in concert with ACEA Biosciences, the xCELLigence RTCA CardioECR system was employed in the first large-scale multisite study to demonstrate the utility of human induced pluripotent stem cell...(PRWeb October 18, 2018)Read the full story at https://www.prweb.com/releases/as_part_of_the_evolving_cipa_paradigm_the_fda_publishes_results_validating_the_utility_of_hipsc_cardiomyocytes_to_detect_drug_induced_proarrhythmia/prweb15850954.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news